DIR Return Create A Forum - Home
       ---------------------------------------------------------
       MS Speaks
  HTML https://msspeaks.createaforum.com
       ---------------------------------------------------------
       *****************************************************
   DIR Return to: TYSABRI (natalizumab)
       *****************************************************
       #Post#: 2013--------------------------------------------------
       (Abst.) Tysabri's effect on disease progression in SPMS
   DIR By: agate
       Date: March 14, 2018, 10:28 am
       ---------------------------------------------------------
       From The Lancet Neurology (March 12, 2018).This study was funded
       by Biogen. It shows that Tysabri didn't change the EDSS score
       for persons with SPMS but did improve arm functioning somewhat,
       using the 9-hole peg test:
       --- Quote ---
       > No treatment effect was observed on the EDSS (OR 1·06, 95% CI
       0·74–1·53; nominal p=0·753) or the T25FW (0·98, 0·74–1·30;
       nominal p=0·914) components of the primary outcome. However,
       natalizumab treatment reduced 9HPT [9-hole peg test] progression
       (OR 0·56, 95% CI 0·40–0·80; nominal p=0·001). In part 1, 100
       (22%) placebo-treated and 90 (20%) natalizumab-treated patients
       had serious adverse events. In part 2, 291
       natalizumab-continuing patients and 274 natalizumab-naive
       patients received natalizumab (median follow-up 160 weeks [range
       108–221]). Serious adverse events occurred in 39 (13%) patients
       continuing natalizumab and in 24 (9%) patients initiating
       natalizumab.
       >
       >
       --- End Quote ---
  HTML http://www.thelancet.com/journals/laneur/article/PIIS1474-4422(18)30069-3/fulltext
       *****************************************************
       Page 1 of 1